What about the departure of executives from 150 listed pharmaceutical companies?

"Pharmaceutical Network Industry Dynamics" September 30, Northeast Pharmaceuticals announced that due to changes in work, Mr. Wei Navy applied to resign as chairman of the company's 8th board of directors and other positions.
, Mr. Wei, resigned and did not hold any administrative position in the company.
On the same day, Guangdong Tai'antang Pharmaceuticals announced that Mr. Chen Wei had applied to resign as a director of the company's fifth board of directors for personal reasons, and Wuhan Huisheng Bio announced that Mr. Wang Tianhui had resigned as deputy general manager and secretary of the board of directors for personal reasons, and that his resignation report would take effect from the date of service to the company's board of directors.
September 25, Chengdu Yuandong Bio issued an announcement, Ms. Zhang Vera for personal reasons, applied to resign from the company's second board of directors independent director, and at the same time resigned from the company's board of directors audit committee chairman, remuneration and appraisal committee members.
the above positions, Ms. Zhang will no longer hold any positions in the company.
incomplete statistics, in September, about 26 listed pharmaceutical companies announced personnel changes, the reasons for leaving the job include work reasons, personal reasons, work division adjustment and so on.
According to statistics, in the first three quarters of this year, a total of about 150 biopharmaceutical listed enterprises issued a notice of the departure of senior executives, including Shanghai Pharmaceuticals, National Pharmaceuticals, Kyushe Tong, Hai wang biological and other 32 enterprises in 2019 revenue of more than 10 billion yuan.
of the 150 pharmaceutical companies, the main reason for the change in positions was "personal reasons", except for the retirement of individual senior executives due to age factors.
the position of change, only the president, vice president level, in the first three quarters of this year, there are 34 listed companies including Haizheng Pharmaceuticals, People's Fu Pharmaceuticals, Guangyuyuan and other changes.
, for example, Zhang Lin'an resigned as vice president of the company in September for personal reasons and will no longer hold any position in the company.
, chairman of Fufu Pharmaceuticals, resigned as chairman of Manfu Pharmaceuticals in March this year due to the adjustment of the division of work.
the reasons for the intense changes in pharmaceutical executives in the first three quarters of 2020, and the industry believes that the main and industry trends are closely related.
years, with the consistent evaluation, volume procurement and other industries to promote policies, pharmaceutical enterprises need to find a way to transform, otherwise they will be eliminated.
in the process of transformation, job changes are inevitable.
august this year, the third batch of collection results dust landed.
a total of 125 enterprises selected, a total of 56 drugs, the average price reduction of 53%, to a high drop of 95%.
products related to malignant tumors, hypertension, diabetes, mental illness and other fields.
with the results of the third batch of collection gradually landed, drug price reduction is inevitable, at the same time, pharmaceutical companies from the previous high level of marketing costs gradually returned to a relatively reasonable range.
, coupled with the consideration of cost control of pharmaceutical companies under the consistent evaluation, as well as the impact of the epidemic and other factors, the performance of many pharmaceutical companies have been affected, including some listed pharmaceutical companies.
, according to incomplete statistics, in the first half of this year, 195 of the 345 A-share listed biopharmaceutical companies experienced a year-on-year decline in revenue, accounting for more than half of the total, and 167 enterprises experienced a year-on-year decline in net profit.
industry pointed out that in the context of pharmaceutical policy and performance pressure, pharmaceutical enterprises' development strategy, personnel adjustment frequently is not surprising, this is not only the performance of enterprise management pressure, but also the transformation and upgrading of China's pharmaceutical industry is accelerating performance.
the adjustment of drug companies may continue for some time to come.
to this, the major pharmaceutical companies only adapt to the new changes, and match the current stage of development of the right talent, in order to go further.